Happy Sunday everyone! No #FITTweetUp today — instead I’m snuggling a sick baby! #priorities 👶🏻Hope everyone is enjoying the weekend (especially those at #TCT2018#TCT18 🙌🏼)
This morning at the #TCT2018 LBCTs it was Stent Wars - stent vs stent vs stent. @Drroxmehran and I share our thoughts on the new gen metallic stents, differentiating features and where the field is headed. Watch here: https://t.co/tDphInAnha
We’ll talk about all the latest Late Breakers and impactful trials to round out the afternoon.
@HeartBobH used to call this whole afternoon the “Nerd Session.” Looking forward to nerding out! #TCT2018
Surprising magnitude of benefit (including improved survival) for catheter mitral valve repair in patients with heart dysfunction, leaky valve & lack of response to medications @NEJM#TCT18@GreggWStone et al
https://t.co/BAObiNE01D@TCTConference
Coapt is positive! Decreased hospitalization and all cause mortality in patients with secondary mr maximally treated for heart failure with mitraclip Vs medical rx alone . NNT = 6 to save a life. Outstanding news for our patients! #tct18#COAPT
COAPT Trial: #TMVR reduced hospitalizations & improved QOL in Heart Failure patients w/ moderate or severe MR vs. medical therapy alone #TCT18https://t.co/KEomXAvrxQ
Live from #tct18 Congrats to #COAPT trial investigators on this potentially practice changing result, @spinneymd how do you reconcile these results with recent Mitral FR trial? Patient selection/operator dependent?
Mitraclip scores a HUGE win : COAPT study at #tct18 improving quality of life, mortality, rehospilalizations. We brought this therapy to the NBHC @BobTeskey@jean_legare@SJRHFoundation -looks like it’s going to stay - and let some patients live their life again.
#COAPT is great news!
#MitraClip Decreased hospitalization and all cause mortality in patients with secondary MR on maximally tolerated GDMT.
NNT to save life = 6 to save a life. #tct18
COAPT vs MITRA-FR
MitraClip in heart failure with severe secondary MR. An astonishing NNT of 6 for mortality in #COAPT (ARR of 17% over 2 years) #TCT18https://t.co/yYiTXqoKxo
The Bayesian in me is very confused. Mitra-FR published a month ago was pretty negative @NEJM
Hands on with SC2000 and a demo of angiography for Transapical approach in #tct18. Experience the easy of use systems from #siemenshealthineers in the pavilion training sessions. #FromTheHeartWall.
Sounds like great session and discussion - need evidence to guide treatment in lower risk patient groups too - requires mega-trials or very long follow up. If funders will not support we will have composite outcomes #TCT18
In reply to
@venkmurthy, @MasriAhmadMD, @ADAlthousePhD, @boback, @bnallamo, @DavidLBrownMD
Great honor presenting our work on #CTO revascularizations at #TCT18. Even though the trip was very short, it was enjoyable. #CreightonCardio#IMCreighton
“It’s a huge advance.” A tiny clip used to repair a heart valve sharply reduced deaths in patients with severe heart failure, a grim diagnosis. https://t.co/IxREAj9kE0
Among patients w/heart failure & secondary mitral regurgitation, transcatheter mitral-valve repair resulted in a lower rate of hospitalization for heart failure and of death than medical therapy alone. The goal for freedom from device-related complications was exceeded. #TCT2018
